Evidence map›Paper›PMID 35229233›Full record

Observational studyNeurocritical care2022

Predicting Clinical Outcomes 7-10 Years after Severe Traumatic Brain Injury: Exploring the Prognostic Utility of the IMPACT Lab Model and Cerebrospinal Fluid UCH-L1 and MAP-2.

Adrian M Svingos, Steven A Robicsek, Ronald L Hayes, Kevin K Wang, Claudia S Robertson, Gretchen M Brophy, Linda Papa, Andrea Gabrielli, H Julia Hannay, Russell M Bauer and 1 more

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Neurocritical care, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Adrian M SvingosBrain Injury Clinical Research Center, Kennedy Krieger Institute, Baltimore, MD, USA.
Steven A RobicsekDepartments of Anesthesiology, Neurosurgery, and Neuroscience, University of Florida, Gainesville, FL, USA.
Ronald L HayesBanyan Biomarkers Inc, Gainesville, FL, USA.
Kevin K WangDepartment of Emergency Medicine, University of Florida, Gainesville, FL, USA.
Claudia S RobertsonDepartment of Neurosurgery, Baylor College of Medicine, Houston, TX, USA.
Gretchen M BrophyPharmacotherapy and Outcomes Science and Neurosurgery, Virginia Commonwealth University Medical College of Virginia Campus, Richmond, VA, USA.
Linda PapaDepartment of Emergency Medicine, Orlando Health Orlando Regional Medical Center, Orlando, FL, USA.
Andrea GabrielliDepartment of Anesthesiology, Perioperative Medicine and Pain Management, University of Miami Miller School of Medicine, Miami, FL, USA.
H Julia HannayDepartment of Psychology, University of Houston, Houston, TX, USA.
Russell M BauerBrain Rehabilitation Research Center, Malcom Randall Department of Veterans Affairs Medical Center, Gainesville, FL, USA.
Shelley C HeatonDepartment of Clinical and Health Psychology, University of Florida, Gainesville, FL, USA. sheaton@ufl.edu.ORCID http://orcid.org/0000-0001-5860-522X

Funding

Research Training in Rehabilitation for Brain Injury and Neurological DisabilityT32HD007414 · NICHD · HUGO W. MOSER RES INST KENNEDY KRIEGER · PI Amy J. Bastian · 1991 to 2026
$6.3M
Biochemical Markers of Traumatic Brain InjuryR01NS052831 · NINDS · UNIVERSITY OF FLORIDA · PI ROBICSEK, STEVEN ANDREW · 2006 to 2010
$4.9M
NICHD NIH HHS T32 HD007414NINDS NIH HHS R01 NS052831
6 · The paper itself

Abstract

backgroundSevere traumatic brain injury (TBI) is a major contributor to disability and mortality in the industrialized world. Outcomes of severe TBI are profoundly heterogeneous, complicating outcome prognostication. Several prognostic models have been validated for acute prediction of 6-month global outcomes following TBI (e.g., morbidity/mortality). In this preliminary observational prognostic study, we assess the utility of the International Mission on Prognosis and Analysis of Clinical Trials in TBI (IMPACT) Lab model in predicting longer term global and cognitive outcomes (7-10 years post injury) and the extent to which cerebrospinal fluid (CSF) biomarkers enhance outcome prediction.

methodsVery long-term global outcome was assessed in a total of 59 participants (41 of whom did not survive their injuries) using the Glasgow Outcome Scale-Extended and Disability Rating Scale. More detailed outcome information regarding cognitive functioning in daily life was collected from 18 participants surviving to 7-10 years post injury using the Cognitive Subscale of the Functional Independence Measure. A subset (n = 10) of these participants also completed performance-based cognitive testing (Digit Span Test) by telephone. The IMPACT lab model was applied to determine its prognostic value in relation to very long-term outcomes as well as the additive effects of acute CSF ubiquitin C-terminal hydrolase-L1 (UCH-L1) and microtubule associated protein 2 (MAP-2) concentrations.

resultsThe IMPACT lab model discriminated favorable versus unfavorable 7- to 10-year outcome with an area under the receiver operating characteristic curve of 0.80. Higher IMPACT lab model risk scores predicted greater extent of very long-term morbidity (β = 0.488 p = 0.000) as well as reduced cognitive independence (β =  - 0.515, p = 0.034). Acute elevations in UCH-L1 levels were also predictive of lesser independence in cognitive activities in daily life at very long-term follow-up (β = 0.286, p = 0.048). Addition of two CSF biomarkers significantly improved prediction of very long-term neuropsychological performance among survivors, with the overall model (including IMPACT lab score, UCH-L1, and MAP-2) explaining 89.6% of variance in cognitive performance 7-10 years post injury (p = 0.008). Higher acute UCH-L1 concentrations were predictive of poorer cognitive performance (β =  - 0.496, p = 0.029), whereas higher acute MAP-2 concentrations demonstrated a strong cognitive protective effect (β = 0.679, p = 0.010).

conclusionsAlthough preliminary, results suggest that existing prognostic models, including models with incorporation of CSF markers, may be applied to predict outcome of severe TBI years after injury. Continued research is needed examining early predictors of longer-term outcomes following TBI to identify potential targets for clinical trials that could impact long-ranging functional and cognitive outcomes.

Indexed as

Brain Injuries, TraumaticBiomarkersGlasgow Coma ScaleHumansMicrotubule-Associated ProteinsPrognosisUbiquitin ThiolesteraseBiomarkersMAP2 protein, humanMicrotubule-Associated ProteinsUbiquitin ThiolesteraseUCHL1 protein, humanBiomarkerCerebrospinal fluidCognitionMicrotubule-associated protein 2OutcomePrognosisTraumatic brain injuryUbiquitin C-terminal hydroxylase-L1

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.